244 related articles for article (PubMed ID: 34345305)
1. Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Hattori K; Takano N; Kazama H; Moriya S; Miyake K; Hiramoto M; Tsukahara K; Miyazawa K
Oncol Lett; 2021 Sep; 22(3):680. PubMed ID: 34345305
[TBL] [Abstract][Full Text] [Related]
2. Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells.
Miyake K; Takano N; Kazama H; Kikuchi H; Hiramoto M; Tsukahara K; Miyazawa K
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35348191
[No Abstract] [Full Text] [Related]
3. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
4. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
5. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K
Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Chang I; Wang CY
J Biol Chem; 2016 Aug; 291(35):18199-209. PubMed ID: 27369083
[TBL] [Abstract][Full Text] [Related]
7. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
8. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Hui KF; Chiang AK
Int J Cancer; 2014 Dec; 135(12):2950-61. PubMed ID: 24771510
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
14. Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.
He Y; Jiang D; Zhang K; Zhu Y; Zhang J; Wu X; Xia J; Zhu Y; Zou L; Hu J; Cui Y; Zhou W; Chen F
J Cancer; 2021; 12(20):6198-6208. PubMed ID: 34539893
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
16. GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress.
Chen Y; Tao Y; Hu K; Lu J
Heliyon; 2023 Sep; 9(9):e19806. PubMed ID: 37809599
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.
Prabhu KS; Ahmad F; Kuttikrishnan S; Leo R; Ali TA; Izadi M; Mateo JM; Alam M; Ahmad A; Al-Shabeeb Akil AS; Bhat AA; Buddenkotte J; Pourkarimi E; Steinhoff M; Uddin S
Cell Death Discov; 2024 May; 10(1):225. PubMed ID: 38724504
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
19. Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Hui KF; Yeung PL; Chiang AK
Oncotarget; 2016 Jan; 7(4):4454-67. PubMed ID: 26683357
[TBL] [Abstract][Full Text] [Related]
20. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Feng M; Wang J; Sun M; Li G; Li B; Zhang H
Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
